Latest Insider Transactions at Cti Biopharma Corp (CTIC)
This section provides a real-time view of insider transactions for Cti Biopharma Corp (CTIC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CTI BIOPHARMA CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CTI BIOPHARMA CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 06
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,223
+30.73%
|
$0
$0.84 P/Share
|
|
Jul 05
2022
|
Michael A Metzger Director |
SELL
Open market or private sale
|
Direct |
91,500
-31.62%
|
$549,000
$6.1 P/Share
|
|
Jul 05
2022
|
Michael A Metzger Director |
BUY
Exercise of conversion of derivative security
|
Direct |
91,500
+45.05%
|
$0
$0.84 P/Share
|
|
Jul 05
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-54.15%
|
$162,000
$6.0 P/Share
|
|
Jul 05
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+35.13%
|
$0
$0.84 P/Share
|
|
Jul 01
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-54.15%
|
$162,000
$6.0 P/Share
|
|
Jul 01
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+35.13%
|
$0
$0.84 P/Share
|
|
Jun 30
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,516
+36.01%
|
$19,032
$2.12 P/Share
|
|
Jun 30
2022
|
Adam R Craig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,183
+21.29%
|
$12,366
$2.12 P/Share
|
|
Jun 17
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
60,000
-72.3%
|
$360,000
$6.13 P/Share
|
|
Jun 17
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+41.53%
|
$120,000
$2.15 P/Share
|
|
Jun 14
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-57.48%
|
$50,000
$5.5 P/Share
|
|
Jun 14
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+36.5%
|
$0
$0.95 P/Share
|
|
Jun 03
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
18,223
-52.21%
|
$109,338
$6.01 P/Share
|
|
Jun 03
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,223
+34.3%
|
$0
$0.84 P/Share
|
|
Jun 02
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-61.82%
|
$162,000
$6.0 P/Share
|
|
Jun 02
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+38.2%
|
$0
$0.84 P/Share
|
|
Jun 01
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-61.82%
|
$162,000
$6.0 P/Share
|
|
Jun 01
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+38.2%
|
$0
$0.84 P/Share
|
|
Dec 31
2021
|
Adam R Craig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,178
+16.01%
|
$6,356
$2.11 P/Share
|
|
Dec 31
2021
|
Bruce J. Seeley EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,241
+6.87%
|
$6,482
$2.11 P/Share
|
|
Dec 31
2021
|
David Kirske EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,817
+19.72%
|
$3,634
$2.11 P/Share
|
|
Dec 02
2021
|
Adam R Craig President and CEO |
BUY
Open market or private purchase
|
Direct |
3,500
+12.17%
|
$3,500
$1.52 P/Share
|
|
Jun 30
2021
|
Bruce J. Seeley EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,164
+7.22%
|
$6,328
$2.12 P/Share
|
|
Jun 30
2021
|
David Kirske EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,782
+24.21%
|
$3,564
$2.12 P/Share
|
|
Jun 30
2021
|
Adam R Craig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+33.33%
|
$10,000
$2.12 P/Share
|
|
Apr 01
2021
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
2,000,000
+15.04%
|
$4,000,000
$2.5 P/Share
|
|
Jan 07
2021
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,000,000
-21.01%
|
$6,000,000
$3.5 P/Share
|
|
Jul 01
2020
|
Adam R Craig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
$0
$0.98 P/Share
|
|
Jul 01
2020
|
David Kirske EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,798
+50.0%
|
$0
$0.98 P/Share
|
|
Jul 01
2020
|
Bruce J. Seeley EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+11.76%
|
$0
$0.98 P/Share
|
|
Feb 09
2018
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Indirect |
699,225
+35.05%
|
$2,097,675
$3.0 P/Share
|
|
Feb 09
2018
|
Bvf Partners L P Director |
BUY
Open market or private purchase
|
Direct |
5,634,108
+50.0%
|
$16,902,324
$3.0 P/Share
|
|
Feb 09
2018
|
Bvf Partners L P Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,487,294
-71.38%
|
-
|
|
Feb 09
2018
|
Bvf Partners L P Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,512,706
-100.0%
|
-
|